This study focuses on patients with resectable pancreatic cancer that has not spread to other parts of the body. The treatment being studied is a combination chemotherapy known as FOLFIRINOX, which consists of four medications: fluorouracil, folinic acid, irinotecan, and oxaliplatin. These medications are given through an infusion into a vein.
The purpose of this research is to determine if giving FOLFIRINOX treatment both before and after surgery (perioperative) leads to better survival outcomes compared to giving it only after surgery (adjuvant). The study will compare these two different approaches to treatment timing in patients who can have their pancreatic cancer surgically removed.
During the study, patients will receive the same combination of medications but at different times in relation to their surgery. The treatment will continue for several weeks, with regular medical check-ups to monitor the patient’s condition. The medications work together to stop cancer cells from growing and dividing, with each drug playing a specific role in fighting the cancer.



Sweden
The Netherlands